Rare Disease & Gene Therapy — July 20, 2026
|
AstraZeneca is anchoring its $80 billion 2030 revenue ambition on rare disease, with the Alexion franchise generating roughly $9.1 billion in 2025, growing 15% at constant exchange rates in Q1 2026, and a late-stage pipeline led by efzimfotase alpha in hypophosphatasia positioned to help offset the Farxiga patent cliff.
Today’s top developments:
|
What to Watch
- AstraZeneca H1/Q2 2026 results (July 27) — the print will show whether rare disease growth, up 15% at constant exchange rates in Q1, can offset the Farxiga patent cliff and keep the $80 billion 2030 revenue ambition on track.
- Kolon TissueGene second Phase 3 readout — osteoarthritis data expected October 2026 will determine whether the cell-based gene therapy program has a regulatory or partnership path, or faces discontinuation.
- 4D-150 pivotal decision — watch whether the two-year PRISM durability profile holds in a larger, more diverse wet AMD population as 4D Molecular Therapeutics advances toward a pivotal trial.
- Calcinosis gene therapy white space — no gene therapy programs are in active clinical development for systemic sclerosis- or dermatomyositis-associated calcinosis, leaving first-mover room for gene editing or RNA platforms targeting mineralization pathways.
This brief highlights the edition’s top stories. Read the full July 20, 2026 edition → for all stories and analysis — or browse the Rare Disease & Gene Therapy archive.